格卡瑞韦/哌仑他韦治疗慢性丙型肝炎病毒感染的真实世界有效性和安全性:来自德国丙型肝炎登记处的数据
基于德国丙型肝炎登记处的前瞻性观察性队列数据,评估格卡瑞韦/哌仑他韦在真实世界中的有效性和安全性。截至2018年7月15日,586例患者中,符合说明书用药者534例(96.7%)获得持续病毒学应答(SVR12),改良意向性分析SVR12率为99.4%(534/537)。药物耐受性良好,不良事件发生率为26%,严重不良事件发生率为2%。
要点
- 在真实世界条件下,格卡瑞韦/哌仑他韦治疗慢性丙型肝炎的SVR12率高达96.7%(意向性分析)和99.4%(改良意向性分析)。
- 大多数患者为初治(90%)、无肝硬化(94%),基因1型(53%)或3型(33%),治疗疗程8周(93%)。
- 不良事件发生率为26%,严重不良事件发生率为2%,仅不足1%的患者因不良事件终止治疗。
核心结论
- 格卡瑞韦/哌仑他韦在真实世界条件下高度有效且耐受性良好。
研究设计与样本
- 德国丙型肝炎登记处是一项正在进行中的非干预性、多中心、前瞻性、观察性队列研究,监测慢性丙型肝炎病毒感染患者。
- 数据收集自2017年8月2日或之后开始使用格卡瑞韦/哌仑他韦并完成筛选访视的患者。
- 截至2018年7月15日,共纳入586例接受格卡瑞韦/哌仑他韦治疗且有SVR12数据、治疗中止、失访或丙型肝炎病毒再感染记录的患者。
主要发现
- 552例(94%)患者接受符合说明书用药;其中基线时大多数为基因1型(53%)或3型(33%)感染,初治(90%),无肝硬化(94%),接受8周治疗(93%)。
- 534例(96.7%)患者获得SVR12(意向性分析)。
- 改良意向性分析(排除治疗中止未获得SVR12或失访的患者)SVR12率为99.4%(n/N=534/537)。
- 记录到1例病毒学失败(复发)和2例丙型肝炎病毒再感染。
- 发生142例(26%)不良事件和9例(2%)严重不良事件;2例(<1%)不良事件导致治疗中止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glecaprevir/pibrentasvir is a pangenotypic direct-acting antiviral regimen approved for treating adults chronically infected with hepatitis C virus (HCV). There are limited real-world data on glecaprevir/pibrentasvir to date. AIM: To evaluate the effectiveness and safety of glecaprevir/pibrentasvir under real-world conditions in the German Hepatitis C-Registry (DHC-R). METHODS: The DHC-R is an ongoing, non-interventional, multicentre, prospective, observational cohort study that monitors patients with chronic HCV infection. Data were collected from patients who initiated glecaprevir/pibrentasvir and completed a screening visit on or after 2 August 2017. The primary effectiveness endpoint was sustained virological response at post-treatment Week 12 (SVR12). Safety and tolerability were also assessed. RESULTS: As of 15 July 2018, 586 patients received glecaprevir/pibrentasvir and had documented SVR12 data, treatment discontinuation, loss to follow-up or HCV reinfection. Five hundred and fifty-two patients (94%) received on-label treatment. At baseline, most on-label patients were infected with HCV genotype 1 (53%) or 3 (33%), HCV treatment-naïve (90%), without cirrhosis (94%), and treated for 8 weeks (93%). Five hundred and thirty-four patients (96.7%) achieved SVR12 (intention-to-treat [ITT] analysis). By modified ITT analysis (excluding patients who discontinued and did not achieve SVR12 or patients lost to follow-up), the SVR12 rate was 99.4% (n/N = 534/537). There was one documented virological failure (relapse) and two documented HCV reinfections. One hundred and forty-two (26%) adverse events (AEs) and 9 (2%) serious AEs occurred; 2 (<1%) AEs led to treatment discontinuation. All patients treated off-label (N = 34) achieved SVR12. CONCLUSION: Glecaprevir/pibrentasvir was highly effective and well tolerated under real-world conditions. Clinical trial number: DRKS00009717 (German Clinical Trials Register, DRKS).
引用
- Berg T, Naumann U, Stoehr A, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther. 2019. PMID: 30874328. doi:10.1111/apt.15222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。